NCT07099391

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

ALTITUDE - ALTernating Induction Therapies to Achieve Undetectable Disease Endpoints: A Phase 1/2 Alternating Dara-RVd/Teclistamab-RVd in Transplant Eligible Standard-risk Newly Diagnosed Multiple Myeloma

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 65 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab, lenalidomide, bortezomib, and dexamethasone) is a safe treatment for people with newly diagnosed multiple myeloma (MM).

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Dara-RVd	This study is a phase 1/2 study design of alternating 6 cycles of Dara-RVd/Tec-RVd induction therapy
DRUG	Tec-RVd	This study is a phase 1/2 study design of alternating 6 cycles of Dara-RVd/Tec-RVd induction therapy

Timeline

• Start date: 2025-07-24
• Primary completion: 2029-07-24
• Completion: 2029-07-24
• First posted: 2025-08-01
• Last updated: 2026-02-11

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study